Misplaced Pages

Latest revision as of 08:32, 30 December 2024

γ-Butyrolactone

Names
Preferred IUPAC name Oxolan-2-one
Other names Dihydrofuran-2(3H)-one GBL Butyrolactone 1,4-Lactone 4-Butyrolactone 4-Hydroxybutyric acid lactone gamma-Hydroxybutyric acid lactone
Identifiers
CAS Number	96-48-0
3D model (JSmol)	Interactive image
ChEBI	CHEBI:42639
ChEMBL	ChEMBL95681
ChemSpider	7029
DrugBank	DB04699
ECHA InfoCard	100.002.282
IUPHAR/BPS	5462
KEGG	C01770
PubChem CID	7302
RTECS number	LU3500000
UNII	OL659KIY4X
CompTox Dashboard (EPA)	DTXSID6020224
InChI InChI=1S/C4H6O2/c5-4-2-1-3-6-4/h1-3H2Key: YEJRWHAVMIAJKC-UHFFFAOYSA-N InChI=1/C4H6O2/c5-4-2-1-3-6-4/h1-3H2Key: YEJRWHAVMIAJKC-UHFFFAOYAC
SMILES O=C1OCCC1
Properties
Chemical formula	C4H6O2
Molar mass	86.090 g·mol
Appearance	Colorless liquid
Odor	Weak characteristic odor, comparable to stale water, synthetic melon aroma or burnt plastic
Density	1.1286 g/mL (15 °C), 1.1296 g/mL (20 °C)
Melting point	−43.53 °C (−46.35 °F; 229.62 K)
Boiling point	204 °C (399 °F; 477 K)
Solubility in water	Miscible
Solubility	Soluble in CCl4, methanol, ethanol, acetone, benzene, ethyl ether
log P	−0.76
Vapor pressure	1.5 kPa (20 °C)
Acidity (pKa)	4.5
Refractive index (nD)	1.435, 1.4341 (20 °C)
Viscosity	1.7 cP (25 °C)
Hazards
Occupational safety and health (OHS/OSH):
Main hazards	Toxic and flammable
GHS labelling:
Pictograms
Signal word	Danger
Hazard statements	H302, H318, H336
Precautionary statements	P264, P270, P280, P301+P312, P305+P351+P338, P403+P233, P501
NFPA 704 (fire diamond)	2 1 1
Flash point	98 °C (208 °F; 371 K) (closed cup)
Autoignition temperature	455 °C (851 °F; 728 K)
Explosive limits	3.6% v/v (lower) 16% v/v (upper)
Lethal dose or concentration (LD, LC):
LD50 (median dose)	1540 mg/kg (oral, rat) >5640 mg/kg (dermal, rabbit)
LC50 (median concentration)	>2.68 mg/kg (rat, 4h)
Safety data sheet (SDS)	Fisher Scientific
Legal status	BR: Class B1 (Psychoactive drugs)
Except where otherwise noted, data are given for materials in their standard state (at 25 °C , 100 kPa). Y verify (what is  ?) Infobox references

γ-Butyrolactone (GBL) or gamma-butyrolactone is an organic compound with the formula O=CO(CH₂)₃. It is a hygroscopic, colorless, water-miscible liquid with a weak characteristic odor. It is the simplest 4-carbon lactone. It is mainly used as an intermediate in the production of other chemicals, such as N-methyl-2-pyrrolidone.

In humans, GBL acts as a prodrug for gamma-hydroxybutyric acid (GHB) and is often used as a recreational drug. GHB acts as a central nervous system (CNS) depressant with effects similar to those of barbiturates.

Occurrence

GBL has been found in extracts from samples of unadulterated wines. This finding indicates that GBL is a naturally occurring component in some wines and may be present in similar products. The concentration detected was approximately 5 μg/mL and was easily observed using a simple extraction technique followed by GC/MS analysis. GBL can be found in cheese flavorings but typically results in a content of 0.0002% GBL in the final foodstuff.

Production and synthesis

γ-Butyrolactone is produced industrially by dehydrogenation of 1,4-butanediol at a temperature of 180–300 °C and atmospheric pressure in the presence of a copper catalyst.

The yield of this process is approximately 95%. The purification takes place with a liquid-gas-phase extraction.

In the laboratory, it may also be obtained via the oxidation of tetrahydrofuran (THF), for example with aqueous sodium bromate. An alternative route proceeds from GABA via a diazonium intermediate.

Reactions

As a lactone, GBL is hydrolyzed under basic conditions, for example in a sodium hydroxide solution into sodium gamma-hydroxybutyrate, the sodium salt of gamma-hydroxybutyric acid. In acidic water, a mixture of the lactone and acid forms exists in an equilibrium. These compounds then may go on to form the polymer poly(4-hydroxybutyrate) as well as the dimer 1,6-Dioxecane-2,7-dione. When treated with a non-nucleophilic base, such as lithium diisopropylamide, GBL undergoes deprotonation of the alpha carbon atom to the carbonyl. The related compound caprolactone can be used to make a polyester in this manner.

Polymerization

The ring-opening polymerization of butyrolactone gives polybutyrolactone. The resulting reverts to the monomer by thermal cracking. It is claimed that poly(GBL) is competitive with commercial biomaterial poly(4-hydroxybutyrate), or P4HB. It is further claimed that poly(GBL) is cheaper to make than P4HB, although both are bio-derived.

Uses

Gamma-Butyrolactone is used as a chemical solvent and a cleaning agent, for example in paint stripping or for cleaning graffiti. Butyrolactone is a precursor to other chemicals. Reaction with methylamine gives NMP, and with ammonia gives pyrrolidone. It is also used as a solvent in lotions and some polymers.

Butyrolactone, with its wide liquid range, chemical stability, and high dielectric constant, is used in electrolytic capacitors as the organic solvent. It is frequently mixed with a small ratio of ethylene glycol, "9:1" being common, to vary internal resistivity.

It has been used as a solvent in various laboratory experiments, e.g., the preparation of methylammonium lead halide.

GBL is used in the synthesis of DPH-362, Atiprosin, Furomazine, GET-73 , Alpertine, & McN 4612-z (page 1451 cmp. 72).

GBL is known to be used in the synthesis of 4-chlorobutyryl chloride. This in turn is used in the synthesis of the butyrophenone sidechain of many antipsychotic drugs (e.g. haloperidol).

It is also known to be employed in the synthesis of 1-bromo-4,4-bis(p-fluorophenyl)butane (the side-chain to the diphenylbutylpiperidine agents).

It was claimed that the reaction of GBL with benzene in the presence of aluminium trichloride could furnish 1-tetralone in a single step.

Another discovered GBL utility is in the synthesis of nicotine (analogs):

Pharmacology

GBL is not active in its own right; its mechanism of action stems from its identity as a prodrug of GHB.

Pharmacokinetics

GBL is rapidly converted into GHB by paraoxonase (lactonase) enzymes, found in the blood. Animals which lack these enzymes exhibit no effect from GBL. GBL is more lipophilic (fat soluble) than GHB, and so is absorbed faster and has higher bioavailability. Because of these pharmacokinetic differences, GBL tends to be more potent and faster-acting than GHB, but has a shorter duration; whereas the related compound 1,4-butanediol (1,4-B) tends to be slightly less potent and slower to take effect but longer-acting than GHB.

Nutritional supplement

Due to its property of being a prodrug of GHB which increases sleep related growth hormone (GH) secretion, GBL was sold as a nutritional supplement after the scheduling of GHB, under the names Revivarant and Renewtrient, until they were banned by the FDA.

Recreational drug

GBL is a prodrug of GHB (naturally produced) and its recreational use comes entirely as a result of this. GBL overdose can cause irrational behavior, severe sickness, coma and death.

To bypass GHB restriction laws, home synthesis kits were introduced to transform GBL and/or 1,4-B into GHB.

GBL has a distinctive taste and odor, described as being comparable to stale water, synthetic melon aroma or burnt plastic. This differs significantly from GHB, which is described as having a decidedly "salty" taste.

Due to the fact that those with limited chemistry knowledge can make GBL with easy-to-get precursors, it has become quite popular among young people in French nightclubs.

Dangers

If taken undiluted by mouth, GBL can cause esophageal and gastro-intestinal irritation. It is possible for oral ingestion of GBL to cause nausea and other similar problems, possibly more so than with GHB.

GHB has biphasic effects, a euphoric effect at low doses (the reason for the term liquid ecstasy), and a sedative effect at higher doses. As a result of this sedation it can cause unconsciousness. When combined with alcohol the increased sedation and risk of vomiting results in a high risk of fatality. Many harm reduction organisations suggest never mixing the two drugs as a result.

There have been news reports of several deaths associated with GBL, usually in combination with alcohol or other depressants.

Gamma-Butyrolactone is often used as a date rape drug.

Addictiveness and dependence

Frequent use of GHB or GBL, even when taken long-term and in moderate doses, does not appear to cause significant physical dependency in the majority of its users. In many people, quitting or temporarily abstaining from use of the drugs is achieved with minimal or no difficulty. However, when consumed in excessive amounts with a high frequency of dosing, physical and psychological dependence can develop. Management of GBL dependence involves considering the person's age, comorbidity and the pharmacological pathways of GBL.

GHB and GBL users can adopt a '24/7' dosing regime. This is where the user has become tolerant to the effects of the drug, increasing the dosage and frequency of dosage simply to avoid withdrawal symptoms.

For those users who do report withdrawal symptoms upon quitting the use of GHB or GBL, symptoms seem to depend on the dosage and the length of time the drug was used. Light to moderate users often experience insomnia and sleep-related problems, whereas heavy, prolonged use can cause severe withdrawal symptoms similar to Benzodiazepine withdrawal syndrome (BWS).

Dose

A milliliter of pure GBL metabolizes to the equivalent 1.65 g of NaGHB, the common form, so doses are measured in the single milliliter range, either taken all at once or sipped over the course of a night.

Legal status

This section needs to be updated. Please help update this article to reflect recent events or newly available information. (January 2020)

Australia: GBL is not classified as a drug but as a health-endangering substance. Legislation entering into force on 1 April 2011 made it possible to handle narcotics for industrial purposes and enabled GBL and 1,4-Butanediol to be classified as controlled substances. As of 2023 there are penalties for possessing, selling or driving under the influence of the substance.

Canada: GBL is a Controlled Substance under Schedule VI of the "Controlled Drugs and Substances Act" in Canada. Schedule VI of the "Controlled Drugs and Substances Act" requires vendors to collect information regarding purchases of GBL. The Act also prohibits the import and export of GBL into or out of Canada classifying it as either an indictable offense punishable with up to 10 years in prison or an offense punishable on summary conviction liable to imprisonment for up to eighteen months. It is not illegal for an individual to possess GBL in Canada.

Germany: GBL is not listed in the narcotics law, but its distribution is controlled. Possession is not illegal, but may be punished according to the Medicines Act, when intended to be sold for human consumption or synthesis of GHB. In recent years, an increase of GBL consumption has been observed due to the prohibition of GHB.

Hong Kong SAR: GBL is a dangerous drug controlled under Schedule 1 of the Dangerous Drugs Ordinance, Cap.134 (with exemption clause at Paragraph 16D). Any person who is found to have in his possession of it not in accordance with this Ordinance can be liable, on conviction upon indictment, a fine of HK$1,000,000 and to imprisonment for 7 years.

Israel: GBL was classified as a proscribed substance from 2007.

Netherlands: GBL is unlike GHB not listed in the narcotics law, but its distribution is controlled. Possession is not illegal but may be punished according to the Medicines Act, when intended to be sold for human consumption or synthesis of GHB.

People's Republic of China: GBL was regulated as a Class III drug precursor since 7 June 2021.

Poland: GBL is classified as a drug. A license is mandatory for the manufacture, processing, reworking, importing, distribution of GBL.

Russia: GBL has been classified as a psychotropic substance since 22 February 2012. Its trafficking is limited, and non-licensed selling, buying or any other use is punishable by imprisonment up to 20 years.

Sweden: GBL is not classified as a drug but as a health-endangering substance. Although recently passed legislation to enter into force on 1 April 2011 will make it possible to handle narcotics for industrial purposes will enable GBL and 1,4-Butanediol to be classified as controlled substances.

United Kingdom: Because of their legitimate uses, regulation 4B of the 2001 regulations makes it lawful to import, export, produce, supply, offer to supply or possess GBL and 1,4-BD, except where a person does so knowing or believing that they will be used for the purpose of human ingestion. Otherwise it is a class B controlled substance.

United States: GBL is regulated as a List I controlled chemical. As a GHB analog, it is also treated as a controlled substance under Schedule I of the Controlled Substances Act if intended for human consumption. Sales and distribution of this product for industrial use is tightly regulated and requires quantity tracing, lock and key storage and 24 hour surveillance and is limited to a very few suppliers who have appropriate DEA registrations and as of 2021 included only Ashland, BASF, and Miami Chemical. Lyondell reportedly stopped commercial sales of this product due to increasingly tight regulations and liabilities but still makes it for internal and downstream production use. To purchase this chemical requires special DEA license and end use certificate approved and a site audit by DEA.

See also

• 1,4-Butanediol
• Succinic anhydride

References

1. Merck Index, 12th edition, 1632.
2. Lide DR, ed. (2009-06-03). CRC Handbook of Chemistry and Physics (90th ed.). Boca Raton, FL: CRC Press. ISBN 978-1-4200-9084-0. Archived from the original on 2011-07-16. Retrieved 2011-07-18.
3. "gamma-Butyrolactone". www.chemsrc.com.
4. Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
5. ^ Schwarz W, Schossig J, Rossbacher R, Pinkos R, Höke H (2019). "Butyrolactone". Ullmann's Encyclopedia of Industrial Chemistry. Weinheim: Wiley-VCH. doi:10.1002/14356007.a04_495.pub2. ISBN 978-3527306732.
6. Schep LJ, Knudsen K, Slaughter RJ, Vale JA, Mégarbane B (July 2012). "The clinical toxicology of γ-hydroxybutyrate, γ-butyrolactone and 1,4-butanediol". Clinical Toxicology. 50 (6): 458–470. doi:10.3109/15563650.2012.702218. PMID 22746383. S2CID 19697449.
7. Vose J, Tighe T, Schwartz M, Buel E (September 2001). "Detection of gamma-butyrolactone (GBL) as a natural component in wine". Journal of Forensic Sciences. 46 (5): 1164–1167. doi:10.1520/JFS15116J. PMID 11569560.
8. Elliott S, Burgess V (July 2005). "The presence of gamma-hydroxybutyric acid (GHB) and gamma-butyrolactone (GBL) in alcoholic and non-alcoholic beverages". Forensic Science International. 151 (2–3): 289–292. doi:10.1016/j.forsciint.2005.02.014. PMID 15939164.
9. ^ "A Change to the Misuse of Drugs Act 1971 : Control of GBL, 1,4-BD, BZP and related piperazine compounds, a further group of anabolic steroids and 2 non-steroidal agents, synthetic cannabinoid receptor agonists and oripavine" (PDF). Home Office Circular. 21. U.K. Home Office. 2009. Archived from the original (PDF) on 2014-10-06. Retrieved 2014-03-31.
10. Metsger L, Bittner S (March 2000). "Autocatalytic Oxidation of Ethers with Sodium Bromate". Tetrahedron. 56 (13): 1905–1910. doi:10.1016/S0040-4020(00)00098-3.
11. "Sandmeyer Reaction of GABA to GBL/GHB". Retrieved 2018-06-14.
12. ^ Micu A (December 12, 2015). "New, fully recyclable and biodegradable plastic could change the world". ZME Science. Retrieved 2015-12-13.
13. Hong M, Chen EY (January 2016). "Completely recyclable biopolymers with linear and cyclic topologies via ring-opening polymerization of γ-butyrolactone". Nature Chemistry. 8 (1): 42–49. doi:10.1038/nchem.2391. PMID 26673263.
14. Hong M, Chen EY (March 2016). "Towards Truly Sustainable Polymers: A Metal-Free Recyclable Polyester from Biorenewable Non-Strained γ-Butyrolactone". Angewandte Chemie. 55 (13): 4188–4193. doi:10.1002/anie.201601092. PMID 26934184.
15. "Gamma-Gamma-Butyrolactone：an industrial solvent". Chemical Book. Retrieved 21 June 2024.
16. "Insider tell you why the GBL Cleaner is the best solution for these nasty dirties and stains". Medium. 16 December 2014. Retrieved 21 June 2024.
17. Niu T, Lu J, Munir R, Li J, Barrit D, Zhang X, et al. (2018). "Stable High-Performance Perovskite Solar Cells via Grain Boundary Passivation". Advanced Materials. 30 (16). doi:10.1002/adma.201706576. PMID 29527750.
18. Anton Ebnother, Ernst Jucker, Erwin Rissi, U.S. patent 3,531,480 (1970 to Sandoz Ag).
19. EP0932597 idem Roberto Cacciaglia, et al. WO1998006690 (Laboratorio Farmaceutico CT SRL).
20. Roberto Cacciaglia & Massimo Ferrari, WO2009062949 (Laboratorio Farmaceutico CT SRL).
21. Sydney Archer, US3562278 & US3639414 (1971 to Sterling Drug Inc).
22. Maryanoff BE, McComsey DF, Gardocki JF, Shank RP, Costanzo MJ, Nortey SO, et al. (August 1987). "Pyrroloisoquinoline antidepressants. 2. In-depth exploration of structure-activity relationships". Journal of Medicinal Chemistry. 30 (8): 1433–54. doi:10.1021/jm00391a028. PMID 3039136.
23. CN101445447A
24. Junying Yuan, et al. WO2011143444 ().
25. "A-TETRALONE". Organic Syntheses. 35: 95. 1955. doi:10.15227/orgsyn.035.0095.
26. Huang K, Ortiz-Marciales M, De Jesús M, Stepanenko V (2009). "A new and efficient approach to the synthesis of nicotine and anabasine analogues". Journal of Heterocyclic Chemistry. 46 (6): 1252–1258. doi:10.1002/jhet.233. PMC 2811585. PMID 20161612.
27. Snead OC (February 1991). "The gamma-hydroxybutyrate model of absence seizures: correlation of regional brain levels of gamma-hydroxybutyric acid and gamma-butyrolactone with spike wave discharges". Neuropharmacology. 30 (2): 161–167. doi:10.1016/0028-3908(91)90199-l. PMID 2030821.
28. ^ Kobilinsky L (2011-11-29). Forensic Chemistry Handbook. John Wiley & Sons. p. 386. ISBN 978-0-471-73954-8.
29. Teiber JF, Draganov DI, La Du BN (September 2003). "Lactonase and lactonizing activities of human serum paraoxonase (PON1) and rabbit serum PON3". Biochemical Pharmacology. 66 (6): 887–896. doi:10.1016/S0006-2952(03)00401-5. PMID 12963475.
30. "Gamma-butyrolactone (GBL) Pre-Review Report" (PDF). 4 June 2012.
31. Van Cauter E, Plat L, Scharf MB, Leproult R, Cespedes S, L'Hermite-Balériaux M, et al. (August 1997). "Simultaneous stimulation of slow-wave sleep and growth hormone secretion by gamma-hydroxybutyrate in normal young Men". The Journal of Clinical Investigation. 100 (3): 745–753. doi:10.1172/JCI119587. PMC 508244. PMID 9239423.
32. "Erowid GHB vault: FDA Warning about Gamma Butyrlactone". Erowid. 1998-11-21. Retrieved 2013-10-10.
33. Meyer J, Quenzer LF (2005). Psychopharmacology: Drugs, the Brain and Behavior. Sinauer. p. 370. ISBN 978-0-87893-534-5.
34. "USDOJ: U.S. Department of Justice Archive National Drug Intelligence Center" (PDF). Usdoj.gov. 2012-06-15. Retrieved 2014-01-22.
35. Galloway GP, Frederick-Osborne SL, Seymour R, Contini SE, Smith DE (April 2000). "Abuse and therapeutic potential of gamma-hydroxybutyric acid". Alcohol. 20 (3): 263–269. doi:10.1016/S0741-8329(99)00090-7. PMID 10869868.
36. "'There could be 100 comas in the year': Paris police chief reacts to rise of GBL, GHB overdoses in clubs". Resident Advisor. Archived from the original on 2018-04-20. Retrieved 2018-04-19.
37. "Drogue : " L'interdiction de vente au public du GBL n'a rien changé à la consommation "". Le Monde.fr (in French). 17 April 2018. Retrieved 2018-04-19.
38. van Nieuwenhuijzen PS, McGregor IS (August 2009). "Sedative and hypothermic effects of gamma-hydroxybutyrate (GHB) in rats alone and in combination with other drugs: assessment using biotelemetry". Drug and Alcohol Dependence. 103 (3): 137–147. doi:10.1016/j.drugalcdep.2009.03.004. PMID 19446408.
39. Edwards R (23 July 2009). "Coroner's 'Russian roulette' warning over GBL party drug". The Telegraph. Retrieved May 1, 2012.
40. "GBL/GHB". London Friend. Retrieved 18 August 2014.
41. "GHB and GBL". GMFA. Archived from the original on 20 June 2020. Retrieved 18 August 2014.
42. Casciani D (23 December 2009). "GBL drug death identified by UK doctors". BBC News. Retrieved May 1, 2012.
43. Karila L, Novarin J, Megarbane B, Cottencin O, Dally S, Lowenstein W, et al. (October 2009). "". Presse Médicale. 38 (10): 1526–1538. doi:10.1016/j.lpm.2009.05.017. PMID 19762202.
44. "GHB addiction, GHB physical n psychological dependency levels". Archived from the original on July 26, 2010.
45. Santos C, Olmedo RE (2017). "Sedative-Hypnotic Drug Withdrawal Syndrome: Recognition And Treatment". Emerg Med Pract. 19 (3): 1–20. PMID 28186869.
46. "Crew 2000 | GHB/ GBL Dependancy [sic] | | Drugs information, advice & support, Scotland, UK". Archived from the original on 2016-03-19. Retrieved 2010-08-06.
47. "LAW AND JUSTICE LEGISLATION AMENDMENT (SERIOUS DRUG OFFENCES AND OTHER MEASURES) ACT 2005 NO. 129, 2005 - SCHEDULE 1 - Serious drug offences".
48. "GHB - Alcohol and Drug Foundation". adf.org.au. Retrieved 2023-07-17.
49. Legislative Services Branch (May 19, 2023). "Consolidated federal laws of Canada, Controlled Drugs and Substances Act". laws-lois.justice.gc.ca.
50. "section 7c of chapter B of part A of the 1st appendix of the Dangerous Drugs Act 1973". www.nevo.co.il.
51. "wetten.nl - Regeling - Opiumwet - BWBR0001941". Wetten.nl (in Dutch). 19 July 2019. Retrieved 19 July 2019.
52. "Webwinkels gestopt met handel in GBL". Emerce (in Dutch). 9 December 2013. Retrieved 9 December 2013.
53. "国务院办公厅关于同意将α-苯乙酰乙酸甲酯等6种物质列入易制毒化学品品种目录的函" (in Simplified Chinese). The State Council - The People's Republic of China. 7 June 2021. Retrieved 11 October 2021.
54. "Główny Inspektorat Farmaceutyczny".
55. "Socialutskottets betänkande 2010/11:SoU5 - Riksdagen".
56. "UK Statutory Instrument 2011 No. 448". 2011-02-18.
57. "The Misuse of Drugs Act 1971 (Amendment) Order 2022".
58. "Information Bulletin: GHB Analogs; GBL, BD, GHV, and GVL". www.justice.gov.

External links

• Erowid on GBL
• "The paint stripper drug that kills". BBC News. October 7, 2005.
• "All About GHB," a NIDA Neuroscience Consortium and OSPC "Cutting Edge" colloquium (27 June 2000 at the Doubletree hotel, Rockville, MD)

• Sedatives
• Gamma-lactones
• Solvents
• GABAB receptor agonists
• GHB receptor agonists
• Designer drugs
• GABA analogues
• Drug-facilitated sexual assault
• Neurotransmitter precursors